HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Humacyte, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors [1] Summary by Relevant Sections Allegations - The class action complaint alleges that during the Class Period, Humacyte's Defendants made materially false and misleading statements and failed to disclose adverse facts about the company's operations and prospects [2] - Specific allegations include: 1. Non-compliance of the Durham, North Carolina facility with good manufacturing practices, including quality assurance and microbial testing 2. Delays in the FDA's review of the Biologics License Application (BLA) due to the need for remediation of these deficiencies 3. Substantial risk to FDA approval of ATEV for vascular trauma as a result of these issues 4. Misleading positive statements regarding the company's business and operations [2] Legal Representation - Bragar Eagel & Squire, P.C. offers assistance to long-term stockholders of Humacyte who may have information or questions regarding the claims [3] Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various complex litigations across state and federal courts [4]